IgG antibodies are commonly used in cancer treatment. They help the body's immune system fight cancer and are being ...

A super-resolution microscopy technique offers an unparalleled glimpse into how monoclonal antibodies bind to their targets ...

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active ...

OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that OST-HER2 is featured in ...

Beigene Ltd. said it is shutting down development of its anti-TIGIT antibody, ociperlimab (BGB-A1217), after the humanized IgG1-variant monoclonal antibody failed a phase III trial in lung cancer. The ...

TIGIT, in particular, has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months after MSD abandoned the development of its anti-TIGIT antibody vibostolimab ...

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early ... high anti-a-synuclein (a-syn) antibody levels on average over 20-fold ...

Researchers say they are exploring therapeutic options to block fatty acid accumulation and immunosuppressive signals between ...

Immunotherapy has revolutionized the way physicians treat patients with cancer. This form of cancer treatment aims to direct the immune system toward the r | Immunology ...

Highlights The acquisition combines IgA antibody assets and expertise of Boston-based TigaTx with Epsilogen's assets and expertise in IgE to create the world's leading pan-isotype cancer antibody ...

OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today provided a regulatory update for its ...